Life Science Company
Boehringer Ingelheim Vetmedica has acquired 0 companies. It has also divested 2 assets.
It’s largest disclosed sale occurred in 2016, when it sold Boehringer Ingelheim Vetmedica - U.S. Feline Canine and Rabies Vaccines to Elanco Animal Health for $885M.
Join Mergr and gain access to Boehringer Ingelheim Vetmedica’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
M&A Total Activity2
- M&A Sell Activity2
- M&A Buy/Sell Connections 2